BC
ELVN icon

Boxer Capital’s Enliven Therapeutics ELVN Stock Holding History

Boxer Capital’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-671,358
Closed -$17.1M – 14
2024
Q3 		$17.1M Hold
671,358
– – 0.84% 34
2024
Q2 		$15.7M Hold
671,358
– – 0.83% 34
2024
Q1 		$11.8M Buy
671,358
+25,300
+4% +$388K 0.58% 41
2023
Q4 		$8.94M Hold
646,058
– – 0.45% 36
2023
Q3 		$8.83M Sell
646,058
-64,586
-9% -$1.09M 0.47% 46
2023
Q2 		$14.5M Hold
710,644
– – 0.67% 40
2023
Q1 		$15.6M Buy
+710,644
New +$14.5M 0.76% 38

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Boxer Capital's ELVN Position: Q4 2024 in Review

Boxer Capital sold out of Enliven Therapeutics (ELVN) in Q4 2024, closing a stake of 671,358 shares — an estimated $17.1M sold.

Boxer Capital first reported a position in ELVN in Q1 2023 and held it in 7 quarters. The position peaked at $17.1M in Q3 2024. 113 funds tracked by Wall St. Rank hold ELVN as of Q4 2024.

  • Boxer Capital reported no remaining Enliven Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Boxer Capital sold 671,358 Enliven Therapeutics shares in Q4 2024, an estimated $17.1M.
  • Boxer Capital first reported a position in Enliven Therapeutics in Q1 2023 and held it in 7 quarters.
  • Boxer Capital's Enliven Therapeutics position peaked at $17.1M in Q3 2024.
  • 113 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q4 2024.

Based on Boxer Capital's 13F filing for Q4 2024.